Clinical Trial Update: Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial [Phase 2]

View source ↗

Summary

The PROTECT CLL trial is a Phase 2 study evaluating vaccination with PCV20 and PPSV23 in patients with CLL-associated immunodeficiency; the study is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• PCV20 (20-valent pneumococcal conjugate vaccine)
• PPSV23 (pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: University of Utah | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING